NOVARTIS for NOVARTIS
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
ACA Pharmaceutical Industry Fee Exclusions R&D Tax Credit Anti-Inversion Tax
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| LEO A FARBER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| JASON BENJAMIN VAN PELT | — |
Budget/Appropriations BUD
Pandemic Influenza Funding FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) FY 2015 Labor HHS Appropriations Bill
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| LEO A FARBER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| JASON BENJAMIN VAN PELT | — |
Copyright/Patent/Trademark CPT
HR3116 MODDERN Cures Act of 2013 Data Exclusivity Trade Secrets Intellectual Property Biopharmaceutical Innovation Policy Issues Biologics Data Protection Issues Draft Legislation on Trade Secret Issues
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| LEO A FARBER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| JASON BENJAMIN VAN PELT | — |
Health Issues HCR
Gene Therapy Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act Dextromethorphan - Age Restrictions - Controlling bulk shipments - PACT Act FSA/HSA - Support reinstating coverage of OTC products HR351/S351 - Medicine Decisions Act of 2011 (IPAB) 340B Drug Discount Program Dual Elibibles Program DQSA Implementation (Track & Trace) Certified Importer Program MDUFA (Medical Device User Fee Act) Implementation Medical Device Tax Repeal Drug Importation Limitations on lawful use of caffeine Reimbursement for medical devices GMP related to manufacturing sites Federal BTC and GMO labeling laws Biosimilars 21st Century Cures PDUFA 340B Drug Discount Program Low-income Subsidy in Part D
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| JASON BENJAMIN VAN PELT | — |
Medicare/Medicaid MMM
Provide Medicare Part B Coverage for Vaccines Covered under Part D Medicaid Coverage of Vaccines
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| LEO A FARBER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| JASON BENJAMIN VAN PELT | — |
Trade (domestic/foreign) TRD
Free Trade Agreements: - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India and Canada IP and market Access Issues Trans-Pacific Partnership FTA Sub-standards Medicines Quality of Medicines Global Intellectual Property Issues Including: - Trade Promotion Authority - Trans-pacific Partnership - Trans Atlantic Trade and Investment Partnership HR3830/S1900 - Bipartisan Congressional Trade Priorities Act of 2014 International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| SARAH HALLER | — |
| JASON BENJAMIN VAN PELT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.